Literature DB >> 606768

The immunizing effect of influenza A/New Jersey/76 (Hsw1N1) virus vaccine administered intradermally and intramuscularly to adults.

H Brown, J A Kasel, D M Freeman, L D Moise, N P Grose, R B Couch.   

Abstract

2The immunogenicity and reactogenicity of inactivated influenza A/New Jersey/76 (Hsw1N1) whole-virus vaccine administered intradermally (40 chick cell-agglutinating units/0.1-ml dose) and intramuscularly (im; 200 chick cell-agglutinating units/0.5-ml dose) to human adults were evaluated. Among 18-24-year-old persons initially free of detectable antibody, intradermal vaccination induced lower titers of hemagglutination-inhibiting antibodies than did im vaccination, and a sequence of intradermal and im vaccinations did not offer any serologic advantage over one im dose. In contrast, persons over the age of 24 who initially lacked detectable antibody had as good a serologic response to intradermal vaccination as to im vaccination. Among individuals who had antibody before vaccination, immunization by either route induced greater increases in titers of hemagglutination-inhibiting antibody than occurred in initially antibody-negative persons, even when the latter were given two doses of vaccine. Somewhat fewer systemic reactions occurred after intradermal than after im vaccination, but the intradermal route was associated with local reactions in almost all vaccinees and with some residual pigmentary changes. These results suggest that intradermal vaccination should be used only in very selected circumstances.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 606768     DOI: 10.1093/infdis/136.supplement_3.s466

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

1.  Efficacy of Influenza Inoculation: Intradermal versus Subcutaneous Route.

Authors:  D Lawee; D Steele; M Gutman; F Demanuele
Journal:  Can Fam Physician       Date:  1981-03       Impact factor: 3.275

Review 2.  Intradermal vaccination using the novel microneedle device MicronJet600: Past, present, and future.

Authors:  Yotam Levin; Efrat Kochba; Ivan Hung; Richard Kenney
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Preclinical evaluation of microneedle technology for intradermal delivery of influenza vaccines.

Authors:  Jason B Alarcon; Andrea Waterston Hartley; Noel G Harvey; John A Mikszta
Journal:  Clin Vaccine Immunol       Date:  2007-02-28

Review 4.  Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.

Authors:  Kwang-Chul Kwon; Dheeraj Verma; Nameirakpam D Singh; Roland Herzog; Henry Daniell
Journal:  Adv Drug Deliv Rev       Date:  2012-10-23       Impact factor: 15.470

Review 5.  Microneedle-based vaccines.

Authors:  Mark R Prausnitz; John A Mikszta; Michel Cormier; Alexander K Andrianov
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

Review 6.  Current evidence on intradermal influenza vaccines administered by Soluvia™ licensed micro injection system.

Authors:  Giancarlo Icardi; Andrea Orsi; Antonella Ceravolo; Filippo Ansaldi
Journal:  Hum Vaccin Immunother       Date:  2012-01-01       Impact factor: 3.452

7.  Safety of intramuscular influenza vaccine in patients receiving oral anticoagulation therapy: a single blinded multi-centre randomized controlled clinical trial.

Authors:  Josep Casajuana; Begoña Iglesias; Mireia Fàbregas; Francesc Fina; Joan-Antoni Vallès; Rosa Aragonès; Mència Benítez; Edurne Zabaleta
Journal:  BMC Blood Disord       Date:  2008-05-29

Review 8.  Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination - A systematic review and meta-analysis.

Authors:  Jenny L Schnyder; Cornelis A De Pijper; Hannah M Garcia Garrido; Joost G Daams; Abraham Goorhuis; Cornelis Stijnis; Frieder Schaumburg; Martin P Grobusch
Journal:  Travel Med Infect Dis       Date:  2020-09-06       Impact factor: 6.211

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.